Kanya Rajangam
Chief Tech/Sci/R&D Officer bei SENTI BIOSCIENCES, INC.
Vermögen: 38 077 $ am 31.03.2024
Profil
Dr. Kanya Rajangam is a Chief Medical & Development Officer at Senti Biosciences, Inc., an Independent Director at Turnstone Biologics Corp.
and an Independent Director at Turnstone Biologics, Inc. She is on the Board of Directors at Turnstone Biologics Corp.
and Turnstone Biologics, Inc. Dr. Rajangam was previously employed as a Chief Medical Officer by Nkarta, Inc., a Chief Medical Officer & Senior Vice President by Atara Biotherapeutics, Inc., a Chief Medical Officer by Cleave Biosciences, Inc., an Executive Director by Nektar Therapeutics, a Senior Medical Director by Onyx Pharmaceuticals, Inc., and an Associate Medical Director by Exelixis, Inc. She received her doctorate degree from Northwestern University and a doctorate degree from St. John's Medical College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SENTI BIOSCIENCES, INC.
0,22% | 01.02.2024 | 101 000 ( 0,22% ) | 38 077 $ | 31.03.2024 |
| 16.10.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Kanya Rajangam
| Unternehmen | Position | Beginn |
|---|---|---|
| SENTI BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01.07.2022 |
| TURNSTONE BIOLOGICS CORP. | Director/Board Member | 01.11.2021 |
Turnstone Biologics, Inc.
 Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Director/Board Member | 01.11.2011 |
Ehemalige bekannte Positionen von Kanya Rajangam
| Unternehmen | Position | Ende |
|---|---|---|
| NKARTA, INC. | Chief Tech/Sci/R&D Officer | 05.06.2022 |
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.09.2018 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01.07.2017 |
| NEKTAR THERAPEUTICS | Director/Board Member | 01.05.2015 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 01.02.2015 |
Ausbildung von Kanya Rajangam
| Northwestern University | Doctorate Degree |
| St. John's Medical College | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| NEKTAR THERAPEUTICS | Health Technology |
| EXELIXIS, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| TURNSTONE BIOLOGICS CORP. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Turnstone Biologics, Inc.
Turnstone Biologics, Inc. BiotechnologyHealth Technology Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada. | Health Technology |
| Senti Biosciences, Inc. |
